Letter: Real-Life Improvement in Quality of Life With Delgocitinib in Chronic Hand Eczema

Abstract

Get full access to this article

View all access options for this article.

References

1. Thyssen

, Johansen

, Linneberg

, et al. The epidemiology of hand eczema in the general population – Prevalence and main findings. Contact Dermatitis. 2010;62(2):75–87.

2. Quaade

, Alinaghi

, Dietz

, et al. Chronic hand eczema: A prevalent disease in the general population associated with reduced quality of life and poor overall health measures. Contact Dermatitis. 2023;89(6):453–463.

3. Capucci

, Hahn-Pedersen

, Vilsbøll

, et al. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31(3):178–184.

4. Bissonnette

, Warren

, Pinter

, et al.; trial investigators. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): Results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461–473; doi: 10.1016/S0140-6736(24)01027-4

5. Gallo

, Stingeni

, Corazza

, et al.; SIDAPA CHE Study Group. Translation and pre-validation of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) in Italian. Ital J Dermatol Venerol. 2024;159(6):682–684.